NCT07532226Recruiting
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
A Real-World, Prospective Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Patients
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 8 Apr 2026
- Start date
- 17 Apr 2026
- Primary completion date
- 10 Dec 2029
- Lead sponsor
- Janssen-Cilag Ltd.
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT07532226
What you commit to
- Study type: Observational
- Planned participants: 200
- From 17 Apr 2026 to the primary completion date, 10 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have already taken a specific interleukin-23 inhibitor (IL-23i) treatment.
- Are receiving combination therapy: 2 or more targeted therapies (biotherapy, Janus kinase \[JAK\] inhibitor, phosphodiesterase 4 (PDE4) inhibitor) indicated for PsA/PsO at the same time
- Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study ( that is, signing of informed consent)
Other illness
- Has a contra-indication to guselkumab according to the SmPC (for hypersensitivity or due to active clinically important infection, example active tuberculosis)
Other
- Unwilling or unable to participate in long-term data collection
- Currently enrolled in any interventional study or any Janssen-Cilag France-sponsored observational clinical study
- Is under guardianship or curatorship, judicial protection, future protection mandate or under family authorization
Who the study is looking for
- Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist with reference to ClASsification criteria for Psoriatic ARthritis (CASPAR)
- Start guselkumab as a first, second, third, or fourth line of disease-modifying antirheumatic drug (bDMARD) therapy for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study
- Initiating guselkumab treatment according to Summary of Product Characteristics (SmPC) indication
- The treatment decision must be taken by the participating rheumatologist prior to, and independently of the patient's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations
- Must have received the information note, given his/her oral agreement and has not objected to the collection of his/her data in accordance with French requirements
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Roger Salengro, CHU Lille Coordinator of this site? Confirm its status | Lille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.